| anti-PD-(L)1 |
| nivolumab followed by ipilimumab |
mML - (neo)adjuvant (NA) | |
mML - NA - all population 9 | |
mML - NA - PDL1 positive 1 | |
mML - 1st line (L1) | |
mML - L1 - all population 7 | |
mML - L1 - BRAF mutant 2 | |
mML - L1 - BRAF wild 3 | |
mML - 2nd line (L2) | |
mML - L2 - all population 11 | |
mML - L2 - BRAF mutant 1 | |
Comparator:
vs ipilimumab followed by nivolumab;
Risk of bias:
low;
some concerns;
high;
NA;